BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

512 related articles for article (PubMed ID: 21997966)

  • 1. The study of Cutaneous Lupus Erythematosus Disease Area and Severity Index in Indian patients with systemic lupus erythematosus.
    Salphale P; Danda D; Chandrashekar L; Peter D; Jayaseeli N; George R
    Lupus; 2011 Dec; 20(14):1510-7. PubMed ID: 21997966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of disease activity and damage in different subtypes of cutaneous lupus erythematosus using the CLASI.
    Bein D; Kuehn E; Meuth AM; Amler S; Haust M; Nyberg F; Sauerland C; Luger TA; Bonsmann G; Kuhn A
    J Eur Acad Dermatol Venereol; 2011 Jun; 25(6):652-9. PubMed ID: 20849444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index (RCLASI): a modified outcome instrument for cutaneous lupus erythematosus.
    Kuhn A; Meuth AM; Bein D; Amler S; Beissert S; Böhm M; Brehler R; Ehrchen J; Grundmann S; Haust M; Ruland V; Schiller M; Schulz P; Ständer S; Sauerland C; Köpcke W; Luger TA; Bonsmann G
    Br J Dermatol; 2010 Jul; 163(1):83-92. PubMed ID: 20394621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicohistological and immunopathological features of patients with cutaneous lupus erythematosus at tertiary dermatology centre in Malaysia.
    Teh YC; Loo CH; Mohd Ali N; Lim AL; Tan WC
    Clin Exp Dermatol; 2022 Aug; 47(8):1490-1501. PubMed ID: 35315538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cutaneous manifestations of systemic lupus erythematosus.
    Yell JA; Mbuagbaw J; Burge SM
    Br J Dermatol; 1996 Sep; 135(3):355-62. PubMed ID: 8949425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural history of disease activity and damage in patients with cutaneous lupus erythematosus.
    Ker KJ; Teske NM; Feng R; Chong BF; Werth VP
    J Am Acad Dermatol; 2018 Dec; 79(6):1053-1060.e3. PubMed ID: 29969701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of the Cutaneous Lupus Disease Area and Severity Index (CLASI) using physician- and patient-assessed health outcome measures.
    Jolly M; Kazmi N; Mikolaitis RA; Sequeira W; Block JA
    J Am Acad Dermatol; 2013 Apr; 68(4):618-623. PubMed ID: 23107310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-nucleosome and anti-chromatin antibodies are present in active systemic lupus erythematosus but not in the cutaneous form of the disease.
    Souza A; da Silva LM; Oliveira FR; Roselino AM; Louzada-Junior P
    Lupus; 2009 Mar; 18(3):223-9. PubMed ID: 19213860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative analysis of subacute cutaneous lupus erythematosus and chronic cutaneous lupus erythematosus: clinical and immunological study of 270 patients.
    Vera-Recabarren MA; García-Carrasco M; Ramos-Casals M; Herrero C
    Br J Dermatol; 2010 Jan; 162(1):91-101. PubMed ID: 19785596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cutaneous lupus erythematosus and the association with systemic lupus erythematosus: a population-based cohort of 1088 patients in Sweden.
    Grönhagen CM; Fored CM; Granath F; Nyberg F
    Br J Dermatol; 2011 Jun; 164(6):1335-41. PubMed ID: 21574972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cutaneous lupus erythematosus disease area and severity index: a responsive instrument to measure activity and damage in patients with cutaneous lupus erythematosus.
    Bonilla-Martinez ZL; Albrecht J; Troxel AB; Taylor L; Okawa J; Dulay S; Werth VP
    Arch Dermatol; 2008 Feb; 144(2):173-80. PubMed ID: 18283174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of cutaneous disease activity in early lupus and its correlation with quality of life: a cross-sectional study.
    Hinduja N; Mv P; Padhee S; Maikap D; Padhan P; Kar HK; Misra R; Srinivas CR; Ahmed S
    Rheumatol Int; 2023 Oct; 43(10):1835-1840. PubMed ID: 37310437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to hydroxychloroquine in Japanese patients with systemic lupus erythematosus using the cutaneous lupus erythematosus disease area and severity index (CLASI).
    Yokogawa N; Kato Y; Sugii S; Inada S
    Mod Rheumatol; 2012 Apr; 22(2):249-55. PubMed ID: 21842436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of smoking on disease severity and antimalarial therapy in cutaneous lupus erythematosus: analysis of 1002 patients from the EUSCLE database.
    Kuhn A; Sigges J; Biazar C; Ruland V; Patsinakidis N; Landmann A; Amler S; Bonsmann G;
    Br J Dermatol; 2014 Sep; 171(3):571-9. PubMed ID: 24673427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apoptosis of keratinocytes and serum DNase I activity in patients with cutaneous lupus erythematosus: relationship with clinical and immunoserological parameters.
    Skiljevic D; Bonaci-Nikolic B; Brasanac D; Nikolic M
    J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):523-529. PubMed ID: 27557471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of skin damage due to cutaneous lupus on quality of life.
    Verma SM; Okawa J; Propert KJ; Werth VP
    Br J Dermatol; 2014 Feb; 170(2):315-21. PubMed ID: 24111880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical characteristics of itch in cutaneous lupus erythematosus: A prospective, multicenter, multinational, cross-sectional study.
    Samotij D; Szczęch J; Antiga E; Bonciani D; Caproni M; Chasset F; Dańczak-Pazdrowska A; Furukawa F; Hasegawa M; Hashizume H; Ikeda T; Islam A; Kim HJ; Lesiak A; Misery L; Mowla MR; Polańska A; Szepietowski JC; Tsuruta D; Verdelli A; Werth VP; Reich A
    Lupus; 2021 Aug; 30(9):1385-1393. PubMed ID: 34000879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic disease in subacute cutaneous lupus erythematosus: a controlled comparison with systemic lupus erythematosus.
    Cohen MR; Crosby D
    J Rheumatol; 1994 Sep; 21(9):1665-9. PubMed ID: 7799346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Keratinocyte and lymphocyte apoptosis: relation to disease outcome in systemic lupus erythematosus patients with and without cutaneous manifestations.
    Salem SA; Farouk HM; Mostafa AA; Hassan IM; Osman WM; Al-Shamy HA; Assaf NY
    Eur J Dermatol; 2010; 20(1):35-41. PubMed ID: 19919906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Skin lesions--an indicator of disease activity in systemic lupus erythematosus?
    Zecević RD; Vojvodić D; Ristić B; Pavlović MD; Stefanović D; Karadaglić D
    Lupus; 2001; 10(5):364-7. PubMed ID: 11403268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.